Skip to Content
News | 08.25.15

Cytovance® Biologics Inc. Announces Acquisition by Hepalink USA Inc.

August 24, 2015 - Morrison Cohen client Cytovance Biologics, Inc., a Great Point Partners I, LP portfolio company, has entered into a definitive agreement to be acquired by Hepalink USA Inc. for $205.68 million in cash. The transaction is expected to close in October, subject to regulatory approval, at which point Cytovance Biologics, a leading biopharmaceutical contract development manufacturing company, will become a fully consolidated subsidiary of Hepalink USA. Click here for details.

Media Inquiries

Please direct media inquiries to the Marketing Department.

Related Practices

Corporate

Clients rely on our corporate lawyers' business judgment, legal advice, market knowledge and analytical skills to identify legal and business issues and solve problems.

Mergers & Acquisitions

Our Mergers & Acquisitions Practice brings together lawyers from our Corporate, Tax, Bankruptcy & Reorganization, Commercial Lending & Finance, Business Litigation, Compensation, Benefits & Employment, Real Estate and Intellectual Property Practices to strategically structure, negotiate and consummate complex business combinations.